Show simple item record

dc.contributor.authorRichards, T
dc.contributor.authorModarage, K
dc.contributor.authorMalik, SA
dc.contributor.authorGoggolidou, P
dc.date.accessioned2021-07-21T13:16:37Z
dc.date.available2021-07-21T13:16:37Z
dc.date.issued2021-06-22
dc.identifier.citationRichards, T., Modarage, K., Malik, S.A. and Goggolidou, P. (2021) The cellular pathways and potential therapeutics of polycystic kidney disease. Biochemical Society Transactions, 49 (3), pp. 171–1188.en
dc.identifier.issn0300-5127en
dc.identifier.pmid34156429 (pubmed)
dc.identifier.doi10.1042/BST20200757en
dc.identifier.urihttp://hdl.handle.net/2436/624211
dc.descriptionThis is an accepted manuscript of an article published by Portland Press in Biochemical Society Transactions on 22/06/2021, available online: https://doi.org/10.1042/BST20200757 The accepted version of the publication may differ from the final published version.en
dc.description.abstractPolycystic Kidney Disease (PKD) refers to a group of disorders, driven by the formation of cysts in renal tubular cells and is currently one of the leading causes of end-stage renal disease. The range of symptoms observed in PKD is due to mutations in cilia-localising genes, resulting in changes in cellular signalling. As such, compounds that are currently in preclinical and clinical trials target some of these signalling pathways that are dysregulated in PKD. In this review, we highlight these pathways including cAMP, EGF and AMPK signalling and drugs that target them and may show promise in lessening the disease burden of PKD patients. At present, tolvaptan is the only approved therapy for ADPKD, however, it carries several adverse side effects whilst comparatively, no pharmacological drug is approved for ARPKD treatment. Aside from this, drugs that have been the subject of multiple clinical trials such as metformin, which targets AMPK signalling and somatostatins, which target cAMP signalling have shown great promise in reducing cyst formation and cellular proliferation. This review also discusses other potential and novel targets that can be used for future interventions, such as β-catenin and TAZ, where research has shown that a reduction in the overexpression of these signalling components results in amelioration of disease phenotype. Thus, it becomes apparent that welldesigned preclinical investigations and future clinical trials into these pathways and other potential signalling targets are crucial in bettering disease prognosis for PKD patients and could lead to personalised therapy approaches.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherPortland Pressen
dc.relation.urlhttps://portlandpress.com/biochemsoctrans/article-abstract/49/3/1171/229086/The-cellular-pathways-and-potential-therapeutics?redirectedFrom=fulltexten
dc.subjectPolycystin-1en
dc.subjectPolycystin-2en
dc.subjectfibrocystinen
dc.subjectPolycystic Kidney Diseaseen
dc.subjectsignallingen
dc.titleThe cellular pathways and potential therapeutics of polycystic kidney diseaseen
dc.typeJournal articleen
dc.identifier.eissn1470-8752
dc.identifier.journalBiochemical Society Transactionsen
dc.date.updated2021-07-19T08:41:14Z
dc.contributor.institutionDepartment of Biomedical Science and Physiology, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, U.K.
pubs.place-of-publicationEngland
dc.date.accepted2021-06-03
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW21072021PGen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2022-06-22en
dc.source.volume49
dc.source.issue3
dc.source.beginpage1171
dc.source.endpage1188
dc.description.versionPublished version
refterms.dateFCD2021-07-21T13:15:53Z
refterms.versionFCDAM


Files in this item

Thumbnail
Name:
Richards_et_al_Cellular_pathwa ...
Embargo:
2022-06-22
Size:
2.179Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/